Skip to main content
Publications
Smith HE, Mackenzie AM, Seddon C , Mould R, Kalampouka I, Malakar P, Needham SR, Beis K, Bell JD, Nunn A, Botchway SW. The use of NADH anisotropy to investigate mitochondrial cristae alignment . Sci Rep. 2024 Mar 12;14(1):5980. doi: 10.1038/s41598-024-55780-5
Marti S, Carsin AE , Sampol J, Pallero M, Aldas I, Marin T, Lujan M, Lalmolda C, Sabater G, Bonnin-Vilaplana M, Penacoba P, Martinez-Llorens J, Tarrega J, Bernadich O, Cordoba-Izquierdo A, Lozano L, Mendez S, Velez-Segovia E, Prina E, Eizaguirre S, Balana-Corbero A, Ferrer J, Garcia-Aymerich J. Higher mortality and intubation rate in COVID-19 patients treated with noninvasive ventilation compared with high-flow oxygen or CPAP . Sci Rep. 2022 Apr 20;12(1):6527. doi: 10.1038/s41598-022-10475-7
Nixon E, Trickey A, Christensen H, Finn A, Thomas A, Relton C, Montgomery C, Hemani G, Metz J, Walker JG, Turner K, Kwiatkowska R, Sauchelli S , Danon L, Brooks-Pollock E. Contacts and behaviours of university students during the COVID-19 pandemic at the start of the 2020/2021 academic year . Sci Rep. 2021 Jun 3;11(1):11728. doi: 10.1038/s41598-021-91156-9
Accordini S, Calciano L, Marcon A, Pesce G, Anto JM, Beckmeyer-Borowko AB, Carsin AE , Corsico AG, Imboden M, Janson C, Keidel D, Locatelli F, Svanes C, Burney PGJ, Jarvis D, Probst-Hensch NM, Minelli C. Incidence trends of airflow obstruction among European adults without asthma: a 20-year cohort study . Sci Rep. 2020 Feb 26;10(1):3452. doi: 10.1038/s41598-020-60478-5
Rebordosa C , Houben E, Laugesen K, Bothner U, Montonen J, Aguado J , Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW . No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study . Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5
Steward T, Mestre-Bach G, Granero R, Sanchez I, Riesco N, Vintro-Alcaraz C, Sauchelli S , Jimenez-Murcia S, Aguera Z, Fernandez-Garcia JC, Garrido-Sanchez L, Tinahones FJ, Casanueva FF, Banos RM, Botella C, Crujeiras AB, Torre R, Fernandez-Real JM, Fruhbeck G, Ortega FJ, Rodriguez A, Menchon JM, Fernandez-Aranda F. Reduced plasma orexin-A concentrations are associated with cognitive deficits in anorexia nervosa . Sci Rep. 2019 May 27;9(1):7910. doi: 10.1038/s41598-019-44450-6
Yosipovitch G, Reaney M, Mastey V, Eckert L, Nelson L , Clark M , Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis . Poster presented at the 2017 American Academy of Dermatology Annual Meeting; March 4, 2017. Orlando, FL. [abstract] J Am Acad Dermatol. 2017 Jun; 76(6 Suppl 1):AB278. doi: 10.1016/j.jaad.2017.04.1082
Strober B, Gottlieb AB, Sherif B , Mollon P, Gilloteau I, McLeod L , Fox T, Mordin M , Gnanasakthy A , Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept . J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Fagundo AB, Jimenez-Murcia S, Giner-Bartolome C, Aguera Z, Sauchelli S , Pardo M, Crujeiras AB, Granero R, Banos R, Botella C, de la Torre R, Fernandez-Real JM, Fernandez-Garcia JC, Fruhbeck G, Rodriguez A, Mallorqui-Bague N, Tarrega S, Tinahones FJ, Rodriguez R, Ortega F, Menchon JM, Casanueva FF, Fernandez-Aranda F. Modulation of irisin and physical activity on executive functions in obesity and morbid obesity . Sci Rep. 2016 Aug 1;6:30820. doi: 10.1038/srep30820
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B , Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1054
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M , Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B , Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B , Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of-life impact than ustekinumab in subjects with moderate to severe plaque psoriasis . Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5[S1]):AB273. Previously presented at the 24th European Academy of Dermatology and Venereology Congress. doi: 10.1016/j.jaad.2016.02.1053
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M , Odom D , Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept . J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.
Kimball AB, Rothman KJ , Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results . J Am Acad Dermatol. 2015 Jan;72(1):115-22. doi: 10.1016/j.jaad.2014.08.050